Pre-trial expectancy did not predict response to psilocybin therapy.

“Speaking to that point a bit in our psilocybin therapy versus escitalopram trial, we measured pre-trial expectancy. And we did it for both conditions. So what kind of improvement do you expect with the Lexapro, the escitalopram at the end of the trial? And what kind of improvement if you go into the psilocybin arm and get two big doses of psilocybin. What kind of improvement do you think you'll see in that arm? And of course, it was a coin flip as to what arm people went into and there was no crossover. What we found was that it was true that we had a sample bias, so most people had higher expectation stations. On average, there were higher expectations for psilocybin and its efficacy or effectiveness versus the SSRI, the Lexapro. However, when we looked at the correlation or the predictive relationship between pre-trial expectancy and response, we saw that pre-trial expectancy for the escitalopram predicted response to escitalopram across virtually every single measure, all these different measures of depression and anxiety and well-being, and I think none of the scales. I'm pretty sure it was none of about 12 or so mental health rating scales. Was there a relationship between pre-trial expectancy? Even though it was high, it didn't predict-- pre-trial expectancy didn't predict response to the psilocybin therapy.”